{"prompt": "['the Adverse Event eCRF, it is important to convey the concept that the pre-existing condition', 'has changed by including applicable descriptors (e.g., \"more frequent headaches\").', '5.3.5.9', 'Lack of Efficacy or Recurrence of Breast Cancer', 'Events that are clearly consistent with breast cancer recurrence should not be recorded as', 'AEs. These data will be captured as efficacy assessment data only. Disease recurrence will', \"be determined based on the investigator's assessment as per institutional practice or the\", 'ACS / ASCO Breast Cancer Survivorship Care Guideline (see Appendix 4). Though a', 'determination of clinical recurrence could be based on symptomatic deterioration, every', 'effort should be made to document recurrence through use of objective criteria. If there is', 'any uncertainty as to whether an event is due to disease recurrence, it should be reported as', 'an AE.', '5.3.5.10', 'Hospitalization or Prolonged Hospitalization', 'Any AE that results in hospitalization (i.e., inpatient admission to a hospital) or prolonged', 'hospitalization should be documented and reported as an SAE (per the definition of SAE in', 'Section 5.2.2), except as outlined below.', 'An event that leads to hospitalization under the following circumstances should not be', 'reported as an AE or an SAE:', 'Hospitalization for respite care', 'Planned hospitalization required by the protocol (e.g., for study drug administration or', 'insertion of access device for study drug administration)', 'Hospitalization for a pre-existing condition, provided that all of the following criteria are', 'met:', '-', 'The hospitalization was planned prior to the study or was scheduled during the study', 'when elective surgery became necessary because of the expected normal', 'progression of the pre-existing condition', '- The patient has not experienced an AE', 'Hospitalization due solely to recurrence of breast cancer', 'An event that leads to hospitalization under the following circumstances is not considered to', 'be an SAE, but should be reported as an AE instead:', 'Hospitalization that was necessary because of patient requirement for outpatient care', 'outside of normal outpatient clinic operating hours', '5.3.5.11', 'Patient Reported Outcome Data', 'Adverse event reports will not be derived from PRO data by the Sponsor, and safety', 'analyses will not be performed using PRO data. Because the data collection processes and', 'intent of interpretation of investigator-assessed AEs and patient-completed questionnaires', 'are inherently different, these data sets will not be reconciled by the Sponsor and should not', 'be used as source documents for AE reporting by the investigator.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '75 / Protocol MO40628, Version 12']['5.4', 'IMMEDIATE REPORTING REQUIREMENTS FROM INVESTIGATOR TO', 'SPONSOR', 'Certain events require immediate reporting to allow the Sponsor to take appropriate', 'measures to address potential new risks in a clinical trial. The investigator must report such', 'events to the Sponsor immediately; under no circumstances should reporting take place', 'more than 24 hours after the investigator learns of the event. The following is a list of events', 'that the investigator must report to the Sponsor within 24 hours after learning of the event,', 'regardless of relationship to study drug:', 'Serious adverse events (defined in Section 5.2.2; see Section 5.4.2 for details on', 'reporting requirements)', 'Adverse events of special interest (defined in Section 5.2.3; see Section 5.4.2 for details', 'on reporting requirements)', 'Pregnancies (see Section 5.4.3 for details on reporting requirements)', 'Overdoses, medication errors, drug abuse, or drug misuse (see Section 5.4.4 for details', 'on reporting requirements)', 'The investigator must report new significant follow-up information for these events to the', 'Sponsor immediately (i.e., no more than 24 hours after becoming aware of the information).', 'New significant information includes the following:', 'New signs or symptoms or a change in the diagnosis', 'Significant new diagnostic test results', 'Change in causality based on new information', \"Change in the event's outcome, including recovery\", 'Additional narrative information on the clinical course of the event', 'Investigators must also comply with local requirements for reporting SAEs to the local health', 'authority and Institutional Review Board (IRB) / Ethics Committee (EC).', '5.4.1', 'Emergency Medical Call Centre', 'To ensure the safety of study patients, an Emergency Medical Call Centre Help Desk will', 'access the Roche Medical Emergency List, escalate emergency medical calls, provide', 'medical translation service (if necessary), connect the investigator with a Roche Medical', 'Responsible (listed above and/or on the Roche Medical Emergency List), and track all calls.', 'The Emergency Medical Call Centre Help Desk will be available 24 hours per day, 7 days', 'per week. Toll-free numbers for the Help Desk, as well as Medical Monitor and Medical', 'Responsible contact information, will be distributed to all investigators.', '5.4.2', 'Reporting Requirements for Serious Adverse Events and Adverse', 'Events of Special Interest', '5.4.2.1', 'Events That Occur prior to Study Drug Initiation', 'After informed consent has been obtained but prior to initiation of study drug, only SAEs', 'caused by a protocol-mandated intervention should be reported. The paper Clinical Trial', 'Serious Adverse Event / Adverse Event of special interest Reporting Form provided to', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '76 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}